[MORE study(raloxifene)].
Itabashi
Akira
A
Department of Clinical Laboratory Medicine, Saitama Medical School.
D015415:Biomarkers / Q000097:blood; D015519:Bone Density; D001943:Breast Neoplasms / Q000517:prevention & control; D002318:Cardiovascular Diseases / Q000517:prevention & control; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D015337:Multicenter Studies as Topic; D015675:Osteocalcin / Q000097:blood; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D020849:Raloxifene Hydrochloride / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D020845:Selective Estrogen Receptor Modulators / Q000009:adverse effects / Q000627:therapeutic use*; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control*; D016896:Treatment Outcome; D020246:Venous Thrombosis / Q000139:chemically induced
D015415:Biomarkers; D020845:Selective Estrogen Receptor Modulators; D015675:Osteocalcin; D020849:Raloxifene Hydrochloride